Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/104362
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study
Author: Doecke, J.
Hartnell, F.
Bampton, P.
Bell, S.
Mahy, G.
Grover, Z.
Lewindon, P.
Jones, L.
Sewell, K.
Krishnaprasad, K.
Prosser, R.
Marr, D.
Fischer, J.
R Thomas, G.
Tehan, J.
Ding, N.
Cooke, S.
Moss, K.
Sechi, A.
De Cruz, P.
et al.
Citation: Alimentary Pharmacology and Therapeutics, 2017; 45(4):542-552
Publisher: Blackwell Publishing Inc.
Issue Date: 2017
ISSN: 0269-2813
1365-2036
Statement of
Responsibility: 
J. D. Doecke ... J. M. Andrews ... On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium, et al.
Abstract: Maintenance anti-tumour necrosis factor-α (anti-TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate response to corticosteroids and immunomodulators.To compare the efficacy and safety of infliximab and adalimumab in clinical practice and assess the value of concomitant immunomodulator therapy.We performed an observational cohort study in consecutive patients with Crohn's disease qualifying for anti-TNFα treatment in Australia and New Zealand between 2007 and 2011. Demographic and clinical data were prospectively recorded to identify independent factors associated with induction and maintenance of response to infliximab or adalimumab, or to either anti-TNFα therapy.Three hundred and twenty-seven patients (183 infliximab, 144 adalimumab) successfully applied for treatment. Eighty-nine percent responded in all groups and median maintenance of response was similar for the two agents. Concomitant immunomodulator with infliximab, but not adalimumab, demonstrated a significantly longer response overall (P = 0.002), and significantly fewer disease and treatment-related complications (P = 0.017). Corticosteroids at baseline, and/or in the preceding 12 months, were associated with a 9-13 times greater risk of disease flare during maintenance treatment as compared to no corticosteroids (P < 0.0001). Maintenance of response was similar in the anti-TNF naïve and anti-TNF experienced subgroups.In this large, real-life study, we demonstrate infliximab and adalimumab to have similar response characteristics. However, infliximab requires concomitant immunomodulator to achieve optimal maintenance of response comparable to adalimumab monotherapy. The results of this study will assist clinicians in further optimising patient care in their day-to-day clinical practice.
Keywords: Australian and New Zealand Inflammatory Bowel Disease Consortium
Rights: © 2016 John Wiley & Sons Ltd
DOI: 10.1111/apt.13880
Published version: http://dx.doi.org/10.1111/apt.13880
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.